Journal Article

Multiplex Real-Time Reverse Transcription PCR for Influenza A Virus, Influenza B Virus, and Severe Acute Respiratory Syndrome Coronavirus 2

Liu, Ji, Zhou, Bin, Spies, Stacey, Rose, Laura E., Shu, Bo, Warnes, Christine, Winchell, Jonas M., Wilson, Malania M., Davis, William G., Hassell, Norman, Kondor, Rebecca J., Benitez, Alvaro J., Limbago, Brandi M., Rambo-Martin, Benjamin L., Winter, Jörn, Wu, Kai-Hui, Barnes, John R., Wentworth, David E., Kirby, Marie K., Camara, Yamundow, Liddell, Jimma, Keller, Matthew W.

2021

Overview

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019, and the outbreak rapidly evolved into the current coronavirus disease pandemic. SARS-CoV-2 is a respiratory virus that causes symptoms similar to those caused by influenza A and B viruses. On July 2, 2020, the US Food and Drug Administration granted emergency use authorization for in vitro diagnostic use of the Influenza SARS-CoV-2 Multiplex Assay. This assay detects influenza A virus at 102.0, influenza B virus at 102.2, and SARS-CoV-2 at 100.3 50% tissue culture or egg infectious dose, or as few as 5 RNA copies/reaction. The simultaneous detection and differentiation of these 3 major pathogens increases overall testing capacity, conserves resources, identifies co-infections, and enables efficient surveillance of influenza viruses and SARS-CoV-2.

• Publisher: U.S. National Center for Infectious Diseases,Centers for Disease Control and Prevention
• Subject: acute respiratory infections / Coronaviruses / COVID-19 / Diagnosis / Flu SC2 Multiplex / Global health / Influenza / Molecular diagnostic techniques / multiplex / Multiplex Real-Time Reverse Transcription PCR for Influenza A Virus, Influenza B Virus, and Severe Acute Respiratory Syndrome Coronavirus 2 / Pandemics / Polymerase chain reaction / Public health / SARS-CoV-2 / Severe acute respiratory syndrome coronavirus 2 / Viruses